Abivax SA Sponsored ADR (ABVX) has released an update.
Abivax SA reported its third-quarter 2024 financials, highlighting cash reserves of EUR 180.5 million, with the capability to fund operations into Q4 2025. The company’s principal debt decreased slightly to EUR 106.3 million from the previous quarter. Abivax continues to focus on advancing its lead drug candidate, obefazimod, in clinical trials for ulcerative colitis.
For further insights into ABVX stock, check out TipRanks’ Stock Analysis page.
